title: A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
authors.affiliation: Biology, University of New Brunswick, Saint John, NB, Canada;
authors.forename: Ming
authors.initials: M
authors.lastname: Han
authors.affiliation: Biology, University of New Brunswick, Saint John, NB, Canada;
authors.forename: Alli
authors.initials: A
authors.lastname: Murugesan
authors.affiliation: Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada;
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis
authors.affiliation: Hematology, Vancouver General Hospital, Vancouver, BC, Canada;
authors.forename: Kevin
authors.initials: K
authors.lastname: Song
authors.affiliation: Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, NS, Canada;
authors.forename: Darrell
authors.initials: D
authors.lastname: White
authors.affiliation: Oncology, Princess Margaret Hospital, Toronto, ON, Canada;
authors.forename: Christine
authors.initials: C
authors.lastname: Chen
authors.affiliation: Oncology, Princess Margaret Hospital, Toronto, ON, Canada;
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Seftel
authors.affiliation: Oncology, London Health Sciences Centre, London, ON, Canada;
authors.forename: Kang
authors.initials: K
authors.lastname: Howsen-Jan
authors.affiliation: Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada;
authors.forename: Donna
authors.initials: D
authors.lastname: Reece
authors.affiliation: Centre for Individualized Medicine, Mayo Clinic Arizona, Scottsdale, AZ;
authors.forename: Keith
authors.initials: K
authors.lastname: Stewart
authors.affiliation: Laboratory Medicine, Saint John Regional Hospital, Saint John, NB, Canada;
authors.forename: Yagang
authors.initials: Y
authors.lastname: Xie
authors.affiliation: Department of Internal Medicine, Queen's University, Kingston, ON, Canada;
authors.forename: Annette E
authors.initials: AE
authors.lastname: Hay
authors.affiliation: Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;
authors.forename: Lois
authors.initials: L
authors.lastname: Shepherd
authors.affiliation: Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;
authors.forename: Marina
authors.initials: M
authors.lastname: Djurfeldt
authors.affiliation: Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;
authors.forename: Liting
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Juravinski Hospital and Cancer Centre and McMaster University, Hamilton ON, Canada; and.
authors.forename: Ralph M
authors.initials: RM
authors.lastname: Meyer
authors.affiliation: Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;
authors.forename: Bingshu E
authors.initials: BE
authors.lastname: Chen
authors.affiliation: Biology, University of New Brunswick, Saint John, NB, Canada; Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Reiman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002170:Canada; D020022:Genetic Predisposition to Disease / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D060046:Maintenance Chemotherapy; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics*; D000071185:Pharmacogenomic Testing / Q000379:methods*; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage; D014182:Transplantation, Autologous
chemical_list: D013792:Thalidomide; D008558:Melphalan; D011241:Prednisone